Fluidigm Adds Gerhard Burbach to Its Board of Directors
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Fluidigm Corporation (NASDAQ:FLDM) today announced that Gerhard F.
Burbach has been appointed to Fluidigm’s Board of Directors. Mr. Burbach
will also join the Board’s Audit and Compensation Committees.
“We are extremely pleased to have a seasoned executive of Gary Burbach’s
caliber joining the board of Fluidigm. Gary has extensive operating
experience, as well as strong strategic skills and expertise that we
believe will contribute to the continued success of Fluidigm,” said Sam
Colella, Fluidigm Chairman of the Board.
“Fluidigm is leading the charge into single-cell genomics. The company’s
extraordinary proprietary microfluidic technology automates the
single-cell workflow and lowers costs so that groundbreaking research in
this exciting new field becomes readily achievable. I look forward to
joining Fluidigm’s Board of Directors and working with the management
team to bring these significant opportunities to reality,” said Mr.
Burbach.
Mr. Burbach currently serves as president, chief executive officer and
director of Thoratec Corporation, a publicly-traded company that
develops, manufactures and markets proprietary medical devices used for
circulatory support.
Mr. Burbach has extensive experience in the medical technology industry.
Prior to joining Thoratec Corporation in January 2006, he served as
president and chief executive officer of Digirad Corporation from April
2005 to January 2006. He also has been a member of Digirad’s board of
directors since 2004. From July 2003 to April 2005, Mr. Burbach served
as president and chief executive officer of Bacchus Vascular, Inc., a
developer of catheter-based medical devices. From January 2001 to July
2003, he served as chief executive officer of Philips Nuclear Medicine,
a division of Philips Electronics, and, before its acquisition by
Philips, worked for four years for ADAC Laboratories, most recently as
president.
Mr. Burbach also spent six years with the management consulting firm of
McKinsey & Company, Inc., where he was most recently a senior engagement
manager in the firm’s healthcare practice.
Mr. Burbach has a B.S. in Industrial Engineering from Stanford
University and an M.B.A. from Harvard Business School.
Use of Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements relating to Fluidigm’s future performance,
opportunities in the single-cell genomics market, and the ability of
management personnel and our board of directors to contribute to the
growth of Fluidigm’s business. These statements involve known and
unknown risks, uncertainties, and other factors that may cause actual
results to be materially different from any future results expressed or
implied by these forward-looking statements, including (among others)
risks relating to research and development activities and the growth of
new and developing markets, Fluidigm’s ability to successfully launch
new products and applications, and competition in Fluidigm’s primary
markets. Information on these and additional risks affecting Fluidigm’s
business and operating results are contained in its filings with the
Securities and Exchange Commission, including its most recently filed
Quarterly Report on Form 10-Q for the quarter ended September 30, 2012.
These forward-looking statements speak only as of the date hereof and
Fluidigm disclaims any obligation to update these statements.
About Fluidigm
Fluidigm (NASDAQ:FLDM) develops, manufactures and markets microfluidic
systems for growth markets in the life science and agricultural
biotechnology, or Ag-Bio, industries. Fluidigm’s proprietary
microfluidic systems consist of instruments and consumables, including
integrated fluidic circuits (IFCs), assays and other reagents. These
systems are designed to significantly simplify experimental workflow,
increase throughput and reduce costs, while providing the excellent data
quality demanded by customers. Fluidigm actively markets four
microfluidic systems, including thirteen different IFCs, to leading
academic institutions, diagnostic laboratories, and pharmaceutical,
biotechnology and Ag-Bio companies. Fluidigm products are marketed for
research purposes only (not for diagnostic use).
For more information, please visit www.fluidigm.com.
Fluidigm, the Fluidigm logo are trademarks or registered trademarks of
Fluidigm Corporation. All other trademarks are the property of their
respective owners.
Fluidigm Corporation Howard High – Press Relations 650-266-6081
(Office) 510-786-7378 (Mobile) howard.high@fluidigm.com
Source: Fluidigm Corporation
SHARE THIS:
SHORT URL: http://bdvt.co/C6n
MEDIA
No media uploaded.
INFO
About
Fluidigm Corporation engages in the development, manufacture, and marketing of microfluidic systems for growth markets in the life science and agricultural biotechnology (Ag-Bio) industries. The company
Press Release $FLDM Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Fluidigm Corporation (NASDAQ:FLDM) today announced that Gerhard F. Burbach has been appointed to Fluidigm’s Board of Directors. Mr. Burbach will also join the Board’s Audit and Compensation Committees.
“We are extremely pleased to have a seasoned executive of Gary Burbach’s caliber joining the board of Fluidigm. Gary has extensive operating experience, as well as strong strategic skills and expertise that we believe will contribute to the continued success of Fluidigm,” said Sam Colella, Fluidigm Chairman of the Board.
“Fluidigm is leading the charge into single-cell genomics. The company’s extraordinary proprietary microfluidic technology automates the single-cell workflow and lowers costs so that groundbreaking research in this exciting new field becomes readily achievable. I look forward to joining Fluidigm’s Board of Directors and working with the management team to bring these significant opportunities to reality,” said Mr. Burbach.
Mr. Burbach currently serves as president, chief executive officer and director of Thoratec Corporation, a publicly-traded company that develops, manufactures and markets proprietary medical devices used for circulatory support.
Mr. Burbach has extensive experience in the medical technology industry. Prior to joining Thoratec Corporation in January 2006, he served as president and chief executive officer of Digirad Corporation from April 2005 to January 2006. He also has been a member of Digirad’s board of directors since 2004. From July 2003 to April 2005, Mr. Burbach served as president and chief executive officer of Bacchus Vascular, Inc., a developer of catheter-based medical devices. From January 2001 to July 2003, he served as chief executive officer of Philips Nuclear Medicine, a division of Philips Electronics, and, before its acquisition by Philips, worked for four years for ADAC Laboratories, most recently as president.
Mr. Burbach also spent six years with the management consulting firm of McKinsey & Company, Inc., where he was most recently a senior engagement manager in the firm’s healthcare practice.
Mr. Burbach has a B.S. in Industrial Engineering from Stanford University and an M.B.A. from Harvard Business School.
Use of Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Fluidigm’s future performance, opportunities in the single-cell genomics market, and the ability of management personnel and our board of directors to contribute to the growth of Fluidigm’s business. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from any future results expressed or implied by these forward-looking statements, including (among others) risks relating to research and development activities and the growth of new and developing markets, Fluidigm’s ability to successfully launch new products and applications, and competition in Fluidigm’s primary markets. Information on these and additional risks affecting Fluidigm’s business and operating results are contained in its filings with the Securities and Exchange Commission, including its most recently filed Quarterly Report on Form 10-Q for the quarter ended September 30, 2012. These forward-looking statements speak only as of the date hereof and Fluidigm disclaims any obligation to update these statements.
About Fluidigm
Fluidigm (NASDAQ:FLDM) develops, manufactures and markets microfluidic systems for growth markets in the life science and agricultural biotechnology, or Ag-Bio, industries. Fluidigm’s proprietary microfluidic systems consist of instruments and consumables, including integrated fluidic circuits (IFCs), assays and other reagents. These systems are designed to significantly simplify experimental workflow, increase throughput and reduce costs, while providing the excellent data quality demanded by customers. Fluidigm actively markets four microfluidic systems, including thirteen different IFCs, to leading academic institutions, diagnostic laboratories, and pharmaceutical, biotechnology and Ag-Bio companies. Fluidigm products are marketed for research purposes only (not for diagnostic use).
For more information, please visit www.fluidigm.com.
Fluidigm, the Fluidigm logo are trademarks or registered trademarks of Fluidigm Corporation. All other trademarks are the property of their respective owners.
Fluidigm Corporation
Howard High – Press Relations
650-266-6081 (Office)
510-786-7378 (Mobile)
howard.high@fluidigm.com
Source: Fluidigm Corporation